Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04022980|
Recruitment Status : Active, not recruiting
First Posted : July 17, 2019
Last Update Posted : January 31, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Brain and Nervous System Eye and Orbit||Drug: Nivolumab||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||13 participants|
|Intervention Model:||Sequential Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 1B Trial Nivolumab Consolidation Following Completion of High-Dose Methotrexate Containing Induction Chemotherapy in Older (≥ 65) Patients With Primary CNS Lymphoma|
|Actual Study Start Date :||March 31, 2020|
|Estimated Primary Completion Date :||December 2024|
|Estimated Study Completion Date :||December 2024|
Experimental: Stage 1
HD-MTX containing induction chemotherapy (per standard of care) followed by Nivolumab consolidation.
Experimental: Stage 2
HD-MTX containing induction chemotherapy (per standard of care) followed by Nivolumab consolidation.
- Safety of Nivolumab in Older Subjects [ Time Frame: Until up to 6 subjects can be adequately assessed for DLT. ]The primary endpoint for the Stage 1 phase of the study is dose-limiting toxicity which will be assessed for each Stage 1 subject using the DLT criteria
- Efficacy of Nivolumab [ Time Frame: 2 years ]The primary endpoint for the Stage 1 phase of the study is the 2-year progression-free endpoint which will be determined for each subject as a binary variable indicating if they are alive and progression-free at 2 years (PFS2)
- Progression Free Survival (PFS) [ Time Frame: 2 years ]PFS is defined as the duration of time from enrollment to first occurrence of either progressive disease or death.
- Overall Survival (OS) [ Time Frame: 2 years ]OS is defined as the duration from enrollment to the date of death from any cause.
- Objective and Complete Response Rates [ Time Frame: approx. 2 years ]Objective response will be determined for each subject as a binary variable indicating if they have achieved a best overall response of CR or PR as determined by the International Criteria for PCNSL (IPCG). Complete response will be determined for each subject as a binary variable indicating if they have achieved a best overall response of CR as determined by the International Criteria for PCNSL(IPCG).
- Conversion Rate from Partial to Complete Response [ Time Frame: approx. 2 years ]Response conversion will be determined for each subject who achieve a best overall response of PR during induction therapy as a binary variable indicating if the subsequently achieve a best overall response of CR to nivolumab consolidation therapy.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||65 Years and older (Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
Subjects must meet all of the following criteria to participate in this study:
- Written informed consent and HIPAA authorization for release of personal health information of subject or subject's legally authorized representative.
- Age ≥ 65 years at the time of consent
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 3 within 14 days prior to day 1 of treatment
- Histological or cytological confirmation of PCNSL, CD20 positive by immunohistochemistry
- Received at least 2 cycles of high-dose methotrexate (HD-MTX) containing induction chemotherapy per institutional standard (R-MPV preferred; see Appendix VI ) without evidence of progressive disease. HD-MTX is typically defined as a MTX dose of at least 3.0 g/m^2.
- Recovered from all reversible acute toxic effects of prior therapy (other than alopecia) to ≤ Grade 1 or baseline)
- Measurable disease at the time of diagnosis (i.e. prior to pre-study HD-MTX containing induction chemotherapy) including lesions that can be accurately measured in 2 dimensions by CT or MRI of brain and with a greatest transverse diameter of ≥ 1 cm. The following disease assessments must have been obtained prior to initiation of pre-study HD-MTX containing induction chemotherapy: MRI of the brain with contrast (and spine with contrast if indicated)
- Deemed poor candidate for whole brain irradiation (WBI) or autologous stem cell transplant (ASCT) due to advanced age, ECOG performance status of 2, or in the opinion of the treating physician, subject would not tolerate the administration of WBI or ASCT for other reasons
- Life expectancy of at least 3 months
Demonstrate adequate organ function as defined below (all screening labs to be obtained within 14 days prior to day 1 of treatment):
- Absolute Neutrophil Count (ANC) ≥ 1000K/mm3
- Platelet Count ≥ 75 K/mm3
- Hemoglobin (Hgb) ≥ 8 g/dL
- Serum creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 50 cc/minute as measured by a 24-hour urine collection or estimated by the Cockcroft and Gault formula
- Bilirubin ≤ 1.5 x upper limit of normal (ULN) (except subjects with Gilbert Syndrome who must have a total bilirubin level of < 3.0 x ULN)
- Aspartate aminotransferase (AST) ≤ 3 x ULN
- Alanine aminotransferase (ALT) ≤ 3 x ULN
Note: since subjects are not enrolled until study treatment is initiated, any labs drawn prior to initiating study treatment on Cycle 1 Day 1 need to meet eligibility criteria since the subject will still be in screening at the time of the lab draw.
- Females of childbearing potential (FCBP) must have a negative serum pregnancy test within 3 days prior to day 1 of treatment. NOTE: Females are considered of child bearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are postmenopausal (at least 12 consecutive months with no menses without an alternative medical cause).
- FCBP must be willing to use a highly effective contraceptive method (i.e., achieves a failure rate of <1% per year when used consistently and correctly) from the time of informed consent until 5 months after treatment discontinuation. Contraceptive methods with low user dependency are preferable but not required. (http://www.hma.eu/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf)
- As determined by the enrolling physician, ability of the subject to understand and comply with study procedures for the entire length of the study.
Subjects must not meet any of the following criteria:
- Documented or suspected ophthalmologic involvement at the time of enrollment as determined by the investigator. Subjects with ophthalmologic involvement prior to or during pre-study induction are allowed if there is no evidence of ophthalmologic involvement prior to enrollment as determined by the investigator.
- Any concurrent systemic involvement by lymphoma outside CNS or intraocular lymphoma without evidence of brain disease
- Any previous chemotherapy or radiation therapy for PCNSL except for treatment with a HD-MTX containing induction chemotherapy. Subjects treated with corticosteroids for PCNSL are allowed.
- Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study)
- Has a known additional malignancy within the past 5 years that is active and/or progressive requiring treatment; exceptions include basal cell or squamous cell skin cancer, in situ cervical or bladder cancer, or carcinoma of the prostrate with a current PSA value of <0.5 ng/mL or other cancer for which subject has completed treatment, been disease-free for at least five years, and is considered by Sponsor-Investigator to be at <30% risk of relapse, or on hormonal therapy for a history of either prostate cancer or breast cancer, provided that there has been no evidence of disease progression during the previous three years.
- Treatment with any investigational drug (including drugs not FDA-approved for the indication for which they are given) within 28 days prior to day 1 of treatment
- Subjects with active, uncontrolled infections (subjects must be afebrile for >48 hours off systemic antibiotics).
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements as determined by the investigator.
- Major surgery and/or radiotherapy within 14 days prior to initiation of study treatment
- Known history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS). NOTE: Testing for HIV must be performed at sites where mandated locally.
- Active infectious hepatitis, type B or C. Subjects with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) may be included if HBV DNA is undetectable.
- Subjects with active interstitial pneumonitis.
- Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04022980
|United States, Massachusetts|
|Dana Farber Cancer Institute|
|Brookline, Massachusetts, United States, 02215|
|United States, North Carolina|
|UNC Hospitals, The University of North Carolina at Chapel Hill|
|Chapel Hill, North Carolina, United States, 27514|
|Levine Cancer Institute|
|Charlotte, North Carolina, United States, 28204|
|United States, Texas|
|The University of Texas - MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Steven Park, MD||Wake Forest University Health Sciences|
Documents provided by Wake Forest University Health Sciences:
|Responsible Party:||Wake Forest University Health Sciences|
|Other Study ID Numbers:||
Pro00036735 ( Other Identifier: Advarra IRB )
LCI-HEM-PCNSL-RMPV-001 ( Other Identifier: Atrium Heatlh )
|First Posted:||July 17, 2019 Key Record Dates|
|Last Update Posted:||January 31, 2023|
|Last Verified:||January 2023|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Antineoplastic Agents, Immunological
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action